Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008) is a research paper published in Gynecologic Oncology Reports (2020). On theSindex it has a DataRank of 0.891. It has been cited 17 times, with 16 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.434
From this paper's citation signal
Citation Network Contribution
0.458
From 12 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 16 citers.
NCI NIH HHS
Grant: U01 CA176067
NCI NIH HHS
Grant: UG1 CA233191
NCI NIH HHS
Grant: U10 CA180822
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: U10 CA180868
NCATS NIH HHS
Grant: UL1 TR001863
NCI NIH HHS
Grant: U24 CA196067
NCI NIH HHS
Grant: UG1 CA233193
National Institutes of Health
Grant: 1U01CA176067-01A1
Integrated genomic analysis of racial disparities in endometrial cancer
National Institutes of Health
Grant: 5U10CA180822-03
NRG Oncology Statistical and Data Management Center
National Institutes of Health
Grant: 2U10CA180822-06
NRG Oncology - Statistical and Data Management Center
National Institutes of Health
Grant: 5U10CA180868-09
NRG Oncology Network Group Operations Center
National Institutes of Health
Grant: 3U10CA180868-02S2
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
National Institutes of Health
FWCI
0.90
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals